PALB2 and pancreatic neoplasm: A large cohort (n = 515) developed by the Pancreatic Cancer Genetic Epidemiology (PACGENE) multicenter consortium has provided a comprehensive analysis of germline mutations occurring in four genes, BRCA1 (1.2%), BRCA2 (3.7%), PALB2 (0.6%), and CDKN2A (2.5%), among familial pancreatic cancer probands [74].